Lung Cancer

Patients with EGFR gene amplification in NSCLC (80% of lung cancers) have significantly better outcomes with tyrosine kinase inhibitors (TKIs);

Used to screen patients with NSCLC suitable for treatment with TKIs;

EGFR gene amplification also occurs in a wide range of tumors, including lung/head and neck/ovarian/cervical/bladder/esophageal cancers.

CNS Tumors

EGFR amplification is most common in astrocytic tumors, and is present in approximately 40% of primary glioblastomas (glioblastomas) and a subset of mesenchymal astrocytomas for which anti-EGFR therapy is indicated.